Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Pacific Biosciences shares plummeted after the company disclosed a revenue shortfall in the first quarter of 2024 and announced cost-cutting measures. The stock value of $PACB dropped significantly, leading to comparisons with other companies like Omniome. The market reaction labeled PacBio as akin to a penny stock.
Utz Brands to Report First Quarter 2024 Financial Results on May 2, 2024 $UTZ. https://t.co/8y1ora4sf7
Pacific Biosciences Shares Crash on Q1 Revenue Shortfall as Firm Reveals Cost Cutting Plans https://t.co/xaMt6YSHlE
The real question everyone should be asking about Pacbio's $PACB stock market plunge is whether they will have an #ASHG24 party this year🤔 https://t.co/LKndkNCbWm
